Download PDF        
September 15, 2011


Lumiphore Announce Brahms diagnostic launch in Europe

Richmond, CA, U.S.A., September 15, 2011. Lumiphore announced the European launch of three diagnostic tests by its partner ThermoFisher Scientific Clinical Diagnostics using Lumiphore’s time-resolved fluorescent reporter technology.

ThermoFisher Clinical Diagnostics has launched three CE marked in vitro diagnostic tests in countries of the European Economic Area (EEA), consisting of the 27 Member States of the EU and EFTA countries, Iceland, Norway, Switzerland, and Liechtenstein. Two test were released in June and one in September 2011:


B·R·A·H·M·S Copeptin us KRYPTOR
is for use in the diagnosis of myocardical infarction. (Released June 7, 2011)

is for use in the differential diagnosis of Polyuria-Polydipsia Syndrome and differential diagnosis of hyponatremia (e.g. Syndrome of Inappropriate ADH Release (SIADH)). (Released September 15, 2011)

is for use in conjunction with clinical evaluation in the confirmation or exclusion of Graves’ disease and differentiation from disseminated autonomy of the thyroid gland. During the course of Graves’ disease, it allows a prognostic statement and thereby constitutes an important decision-making aid in the management of the treatment. In pregnant women with Graves’ disease, the test provides an aid for assessing the risk of the onset of hyperthyroidism in the fetus. (June 9, 2011)

These diagnostic tests use Lumiphore’s Lumi4® technology, a new class of fluorescent-metal lanthanide detection reagents patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley.
These new reagents bring the benefits of lanthanide-based homogenous assays to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore’s new reporter technology,” said Darren Magda, Lumiphore’s Vice President of Research & Development.

Lanthanides are exceptional due to their long fluorescent lifetime delays that enable time gating and a dramatic drop in background noise when sensitized by the appropriate organic cage. Lumiphore’s unique patent family is focused on a novel cage structure surrounding the terbium ion which enables them to be used as extremely efficient time resolved fluorescence (TRF) reporters, and Förster resonance energy transfer (FRET) donors in proximity binding assays. These complexes have long emission lifetimes and offer a number of major advantages over existing fluorophores used for detection, including very high signal-to-noise ratio, stability, elimination of photo-bleaching, and multiplexing.
Thermo Fisher Scientific Clinical Diagnostics is using Lumiphore’s next generation terbium-donors in its BRAHMS-branded current and future assays.

“Using Lumi4®-Tb to replace the current Europium Cryptate will not only potentially increase sensitivity of certain BRAHMS diagnostic tests, but we are hopeful BRAHMS will consider the development of multiplexed assays - measuring 3-4 parameters in one test sample,” explained Dr. Blose. The impact of multiplexing - multiple diagnostic tests in one sample –on the daily clinical routine spares patients the burden of repeated blood withdrawal and in the same time save time and costs for the hospital.

About Lumiphore, Inc.

Based in Richmond, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. For more information about Lumiphore, log onto Lumi4® is a registered mark of Lumiphore, Inc.

Media Contact

Lumiphore, Inc.
Stephen H. Blose
Chief Business Officer